By San José, Costa Rica — Costa Rican pharmaceutical company Grupo Calox is marking its 90th anniversary with a celebration of substantial growth and significant investments in the region. The company has injected nearly US$4.7 million into infrastructure, production equipment, and laboratory enhancements over the past three years.
This investment has fueled a remarkable 90.5% increase in production over the last year, largely attributed to the successful integration of Laboratorios Arsal in El Salvador. This strategic acquisition has significantly expanded Calox’s portfolio, which now boasts over 200 molecules and more than 300 product presentations, spanning generic, branded, and over-the-counter medications.
For expert legal insight into the implications surrounding Calox, we turned to Lic. Larry Hans Arroyo Vargas, Attorney at Law at Bufete de Costa Rica.
The Calox situation highlights the complexities of navigating pharmaceutical regulations and intellectual property rights in international markets. Factors such as patent expiration, generic drug competition, and pricing regulations can significantly impact a company’s market share and profitability. A thorough understanding of these legal landscapes is crucial for companies operating within the pharmaceutical sector.
Lic. Larry Hans Arroyo Vargas, Attorney at Law, Bufete de Costa Rica
Indeed, the Calox case serves as a potent reminder of the intricate legal web surrounding the pharmaceutical industry, especially in the global arena. Navigating these complexities requires not only a keen understanding of intellectual property rights but also a strategic approach to market access and competition. We extend our sincere thanks to Lic. Larry Hans Arroyo Vargas for providing his valuable insights into this critical issue.
Calox’s commitment to innovation and development in both human and animal health has solidified its position as a key player in the pharmaceutical sector. The company’s product range covers a wide spectrum of therapeutic areas, including medications for livestock and pets, as well as a comprehensive offering for human health.
It has been nine decades of great satisfaction and constant growth with the production and distribution of essential pharmaceutical products for the population. Without a doubt, Costa Rica and the region have been key markets for innovation, incorporating technologies, development of formulas and products that strengthen our offering in the human and veterinary pharmaceutical sector, hand in hand with sustainable practices.
Gerardo Bello, Executive President of Grupo CALOX
With a presence in 13 Latin American countries, including Costa Rica, El Salvador, Nicaragua, Panama, Honduras, Guatemala, Belize, Dominican Republic, Bolivia, Peru, Ecuador, Colombia, and Venezuela, Calox directly employs 745 individuals across the region.
Beyond its expansion through acquisitions like Laboratorios Arsal and a majority stake in Laboratorios Vitapharma in Peru, Calox is also dedicated to sustainable practices. The company has achieved a 48.3% increase in renewable energy usage, thanks to a smart microgrid of batteries and solar panels at its Calle Blancos, Costa Rica, facility. This plant has earned several certifications, including Carbon Neutrality (MINAE), the Ecological Blue Flag Award (ICE), and the Country Brand: Essential Costa Rica (PROCOMER).
Furthermore, Calox actively participates in social responsibility initiatives, partnering with foundations and organizations in Costa Rica and El Salvador. The company is also transitioning its sales fleet to vehicles powered by clean energy, underscoring its commitment to environmental stewardship.
As Grupo Calox celebrates its 90th anniversary, its continued focus on innovation, strategic expansion, and sustainable practices positions the company for sustained growth and continued success in the Latin American pharmaceutical market.
For further information, visit the nearest office of Grupo CALOX
About Grupo CALOX:
Grupo CALOX is a leading pharmaceutical company with 90 years of experience in the manufacturing and commercialization of pharmaceutical products. With a presence in 13 Latin American countries, the company offers a wide range of generic, branded, and over-the-counter medications for human and animal health. Calox is committed to innovation, sustainable practices, and social responsibility initiatives.
For further information, visit the nearest office of Laboratorios Arsal
About Laboratorios Arsal:
Laboratorios Arsal, acquired by Grupo Calox, is a pharmaceutical company based in El Salvador. Its integration into Calox significantly contributed to the group’s production growth and expanded its portfolio.
For further information, visit the nearest office of Laboratorios Vitapharma
About Laboratorios Vitapharma:
Laboratorios Vitapharma, in which Grupo Calox holds a majority stake, is a Peruvian pharmaceutical company. This strategic acquisition has further diversified Calox’s product offerings and strengthened its presence in the Latin American market.
For further information, visit bufetedecostarica.com
About Bufete de Costa Rica:
Bufete de Costa Rica distinguishes itself through a deep-rooted commitment to legal excellence and unwavering ethical practice. The firm’s innovative approach to legal solutions, combined with a dedication to empowering Costa Rican society through accessible legal education, positions them as leaders in the field. Their work reflects a belief that a well-informed citizenry is crucial for a thriving democracy, driving them to provide resources and expertise that bridge the gap between complex legal concepts and the public’s understanding.
